Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Conditions: Multiple Endocrine Neoplasia; Recurrent Thyroid Gland Carcinoma; Thyroid Gland Medullary CarcinomaInterventions: Drug: Sorafenib Tosylate; Other: Pharmacological Study; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Active, not recruiting - verified September 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Multiple Endocrine Neoplasia | Multiple Endocrine Neoplasia Syndrome | Research | Study | Thyroid | Thyroid Cancer